F-18 FDG
ApprovedSmall molecule
F-18 FDG is one of 104 small molecule programs targeting Renal Cell Carcinoma. It is currently in Approved.
3
Indications
6
Total Trials
1
Active Trials
103
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
363 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Cabometyx
Bristol-Myers SquibbPhase 3
Votrient
NovartisPhase 3
Nexavar
BayerPhase 3
Lenvima
EisaiPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Tecentriq
RochePhase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Imfinzi
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
TKI258
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Renal Cell Carcinoma1 trial
Biomarkers1 trial
Recurrent1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-18 FDG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SStanford University